{"id":747710,"date":"2023-04-14T07:03:17","date_gmt":"2023-04-14T11:03:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/"},"modified":"2023-04-14T07:03:17","modified_gmt":"2023-04-14T11:03:17","slug":"bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/","title":{"rendered":"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting<\/b><\/p>\n<p>CAMBRIDGE, England &amp; BOSTON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nBicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (<i>Bicycle<\/i><i><sup>\u00ae<\/sup><\/i>) technology, today announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023.<\/p>\n<p><b>Poster Presentation Details:<\/b><\/p>\n<p><b>Title:<\/b> Modulation of natural killer cell immune response to tumor with novel synthetic tumor-immune cell agonist, NK-TICA<sup>\u2122<br \/>\n<br \/><\/sup><b>Session Title: <\/b>Immunomodulatory Agents and Interventions 1<br \/>\n<br \/><b>Date and Time:<\/b> Monday, April 17, 2023 at 9:00 a.m. ET<br \/>\n<br \/><b>Abstract Number:<\/b> 1806<br \/>\n<br \/><b>Speaker\/Lead Author<\/b>: Fay Dufort, Bicycle Therapeutics<\/p>\n<p><b>Title:<\/b> Development of in vivo models for evaluation of NK-TICA<sup>\u2122<\/sup>, novel Bicycle\u00ae tumor-targeted immune cell agonist<sup>\u00ae<\/sup> designed to engage NK cells<br \/>\n<br \/><b>Session Title: <\/b>Immunomodulatory Agents and Interventions 1<br \/>\n<br \/><b>Date and Time:<\/b> Monday, April 17, 2023 at 9:00 a.m. ET<br \/>\n<br \/><b>Abstract Number:<\/b> 1826<br \/>\n<br \/><b>Speaker\/Lead Author:<\/b> Lukas Stanczuk, Bicycle Therapeutics<\/p>\n<p><b>Title:<\/b> EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a Bicycle<sup>\u00ae<\/sup> tumor-targeted immune cell agonist<sup>\u00ae<br \/>\n<br \/><\/sup><b>Session Title: <\/b>Immunomodulatory Agents and Interventions 2<br \/>\n<br \/><b>Date and Time:<\/b> Monday, April 17, 2023 at 9:00 a.m. ET<br \/>\n<br \/><b>Abstract Number:<\/b> 1832<br \/>\n<br \/><b>Speaker\/Lead Author:<\/b> Lia Luus, Bicycle Therapeutics<\/p>\n<p><b>Title:<\/b> Phase 1\/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with Nectin-4 associated advanced malignancies<br \/>\n<br \/><b>Session Title: <\/b>Phase I and First-in-Human Clinical Trials in Progress<br \/>\n<br \/><b>Date and Time:<\/b> Tuesday, April 18, 2023 at 1:30 p.m. ET<br \/>\n<br \/><b>Abstract Number:<\/b> CT253<br \/>\n<br \/><b>Speaker\/Lead Author:<\/b> Thomas R. Jeffry Evans, MBBS: School of Cancer Sciences, University of Glasgow<\/p>\n<p>\nThe posters will be made available on the Publications section of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bicycletherapeutics.com%2F&amp;esheet=53380896&amp;newsitemid=20230414005025&amp;lan=en-US&amp;anchor=bicycletherapeutics.com&amp;index=1&amp;md5=26ba8100c561b8221de964afd6e29e47\">bicycletherapeutics.com<\/a> following the presentations.<\/p>\n<p><b>About Bicycle Therapeutics<\/b><\/p>\n<p>\nBicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC\u2122) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA\u2122 targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I\/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I\/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bicycletherapeutics.com%2F&amp;esheet=53380896&amp;newsitemid=20230414005025&amp;lan=en-US&amp;anchor=bicycletherapeutics.com.&amp;index=2&amp;md5=8c245d7116993ad33e7148cfa785e3b2\">bicycletherapeutics.com.<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230414005025\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230414005025\/en\/<\/a><\/span><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>David Borah, CFA<br \/>\n<br \/>SVP, Capital Markets &amp; Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:david.borah@bicycletx.com\">david.borah@bicycletx.com<br \/>\n<\/a><br \/>617-203-8300<\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Argot Partners<br \/>\n<br \/>Sarah Sutton<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:bicycle@argotpartners.com\">bicycle@argotpartners.com<br \/>\n<\/a><br \/>212-600-1902<br \/>\n<\/p>\n<p><b>KEYWORDS:<\/b> Florida Massachusetts Europe United States United Kingdom North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting CAMBRIDGE, England &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211; Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023. Poster Presentation Details: Title: Modulation of natural killer cell immune response to tumor with novel synthetic tumor-immune cell agonist, NK-TICA\u2122 Session Title: Immunomodulatory Agents and Interventions 1 Date and Time: Monday, April 17, 2023 at 9:00 a.m. ET Abstract Number: 1806 Speaker\/Lead Author: Fay Dufort, Bicycle Therapeutics Title: Development of in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-747710","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting CAMBRIDGE, England &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211; Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023. Poster Presentation Details: Title: Modulation of natural killer cell immune response to tumor with novel synthetic tumor-immune cell agonist, NK-TICA\u2122 Session Title: Immunomodulatory Agents and Interventions 1 Date and Time: Monday, April 17, 2023 at 9:00 a.m. ET Abstract Number: 1806 Speaker\/Lead Author: Fay Dufort, Bicycle Therapeutics Title: Development of in &hellip; Continue reading &quot;Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-14T11:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting\",\"datePublished\":\"2023-04-14T11:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/\"},\"wordCount\":498,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/\",\"name\":\"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-04-14T11:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting - Market Newsdesk","og_description":"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting CAMBRIDGE, England &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211; Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023. Poster Presentation Details: Title: Modulation of natural killer cell immune response to tumor with novel synthetic tumor-immune cell agonist, NK-TICA\u2122 Session Title: Immunomodulatory Agents and Interventions 1 Date and Time: Monday, April 17, 2023 at 9:00 a.m. ET Abstract Number: 1806 Speaker\/Lead Author: Fay Dufort, Bicycle Therapeutics Title: Development of in &hellip; Continue reading \"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-14T11:03:17+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting","datePublished":"2023-04-14T11:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/"},"wordCount":498,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/","name":"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-04-14T11:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230414005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-to-present-at-the-2023-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=747710"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747710\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=747710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=747710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=747710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}